Large B Cell Lymphoma

P1, N=12, Completed, The Methodist Hospital Research Institute | Active, not recruiting --> Completed

Clinicians must maintain a high index of suspicion for IVLBCL in patients with unexplained neurological symptoms, persistent fever, and elevated interleukin-10, even when imaging is non-specific. Early biopsy and multidisciplinary evaluation are essential for timely diagnosis and management.

The patient received high-dose methotrexate-based chemotherapy according to the DeAngelis protocol, combined with rituximab, selected to optimise disease control while minimising the neurotoxicity associated with whole-brain radiotherapy. She achieved visual recovery to 6/9 and regression of the central nervous system (CNS) lesion. This case underscores the importance of recognising pathognomonic retinal signs and employing molecular immunophenotyping to enable timely, life-saving, neuro-sparing therapy.

P1, N=16, Completed, Calibr, a division of Scripps Research | N=36 --> 16 | Trial completion date: Aug 2036 --> Oct 2025 | Trial primary completion date: Aug 2036 --> Oct 2025 | Enrolling by invitation --> Completed

P2, N=30, Not yet recruiting, Ruijin Hospital

Post-CAR-T salvage therapy consisted of heterogeneous regimens, most commonly polatuzumab-bendamustine-rituximab and CD20 × CD3 bispecific antibody monotherapy. Response rates and short-term survival varied across approaches, with bispecific antibody monotherapy having the highest ORR (65%) and favorable 1-year outcomes (OS 56%; EFS 43%). In this contemporary multicenter cohort, salvage therapy after CAR-T failure achieved objective but often short-lived responses, with outcomes driven by relapse timing after CAR-T infusion rather than the line of prior CAR-T therapy, supporting individualized treatment selection in this high-risk setting.

Integration of artificial intelligence and point-of-care manufacturing may further streamline production and patient selection. Continued innovation will determine the long-term impact of CAR T-cell therapy as a scalable pillar of precision hematologic oncology.

Amplification of 9p24.1, causing PD-L1 overexpression, plays a significant role in EBV-positive DLBCL and EBV-positive cHL, whereas EBVMCU, DLBCL-CI, FA-DLBCL, and LyG primarily depend on an (local) immunosuppressive condition. In conclusion, the molecular pathogenesis of EBV LPD is less reliant on driver mutations and instead rely on EBV latent genes and immune evasion; both factors provide promising targets for future therapy.

P1/2, N=217, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2028 --> Jun 2027

Post-treatment positron emission tomography/computed tomography (PET/CT) confirmed complete metabolic remission. This case highlights an exceptionally rare and aggressive presentation of HGBL-NOS with extensive extranodal dissemination involving 11 organs in the absence of lymphadenopathy, underscoring the importance of early integrated diagnostic approaches and prompt initiation of intensive chemotherapy to achieve favorable outcomes.

P2/3, N=57, Not yet recruiting, University Of Cologne

Both current classifications recognize some categories of BCL2-R negative FL including the "predominantly diffuse FL" (WHO-HAEM5) (overlapping with the "BCL2-R negative/CD23 positive follicle center lymphoma" according to the ICC) often presenting in the inguinal region with an indolent course; the paediatric-type FL and the testicular FL affecting children or young adults. The recently described "follicle center lymphoma of the lower female genital tract" shows some similarities with primary cutaneous follicle center lymphoma.